A targeted oral hygiene routine for Ozempic users should include: Brush twice daily Use a soft-bristled brush Floss or use interdental brushes daily Use an alcohol-free mouthwash Apply a fluoride gel or mousse Wait 3060 minutes after vomiting Use a saliva substitute or dry mouth spray Chew sugar-free gum Consistency in these practices, combined with regular dental visits, greatly reduces the risk of Ozempic-related dental problems
Broussard blends medical expertise with personal passion, having lost over 100 pounds herself following the birth of her first child
[8] The biostructural roles of isopeptide bonds include blood clotting [9] (for wound healing), extracellular matrix upkeep, [10] the apoptosis pathway, [10] modifying micro-tubules, [11] and forming pathogenic pili [12] in bacteria
Pol MerkurLekarski
Retatrutide is a peptide-based weight loss medication for type 2 diabetes and obesity
1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently one of the most important public health issues in the world because it is directly related to metabolic disorders such as obesity, insulin resistance, and type 2 diabetes mellitus (T2DM) ( MASLD is particularly notorious for being able to accelerate the development of T2DM, a chronic metabolic disease characterized by hyperglycemia, IR, and beta cell failure ( The main pathophysiological mechanisms through which Insulin resistance (IR), hepatic lipid accumulation, and low-grade inflammation lead to MASLD and T2DM have been described ( 2 Epidemiological data With the prevention and control of many infectious diseases, Non-Communicable Diseases (NCDs) have become the leading global diseases burden ( 2.1 Global prevalence and trends of MASLD and T2DM MASLD has recently become the leading cause of chronic liver disease (CLD) and is now recognized as the most common liver disease ( Epidemiological studies indicate that MASLD is increasing rapidly worldwide, with some studies reporting a prevalence of over 40% in high-risk male populations, compared to approximately 26% in females ( It has been found that MASLD boosts the risk of developing T2DM by two to five times according to the level of hepatic fibrosis and metabolic dysfunction ( 2.2 Ethnic and racial disparities in MASLD and T2DM prevalence Racial and ethnic inequalities in the rates of MASLD and T2DM have been noted
